# ArriVent BioPharma Reports Positive Phase 1b Trial Results for Lung Cancer Drug Firmonertinib

- URL: https://stocks.freetheai.org/news/arrivent-biopharma-reports-positive-phase-1b-trial-results-for-lung-cancer-drug-95bcdb
- Published: 2026-10-19T12:13:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:AVBP](https://stocks.freetheai.org/symbols/NASDAQ-AVBP)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

ArriVent BioPharma, Inc. (AVBP) announced the publication of Phase 1b clinical study results evaluating its investigational drug firmonertinib in patients with EGFR PACC-mutant non-small cell lung cancer. Among front-line patients receiving a 240 mg daily dose, the treatment achieved a confirmed overall response rate of 68% and a median progression-free survival of 16.0 months, compared to a 43% response rate and 11.1 months of survival for those on a 160 mg dose.

The therapy also demonstrated activity in the central nervous system, recording a 47% confirmed intracranial overall response rate in patients with brain metastases, with 41% achieving complete responses. In addition, 80% of evaluable patients showed early clearance of circulating tumor DNA by the third treatment cycle, which strongly correlated with higher response rates and longer progression-free survival. Safety outcomes remained manageable and aligned with earlier trials.

Investors will be monitoring the next stage of development as ArriVent BioPharma, Inc. advances firmonertinib into its global Phase 3 ALPACCA trial to evaluate the treatment in a larger patient population.

## Key points

- A 240 mg dose of firmonertinib achieved a 68% response rate and 16.0 months median progression-free survival in front-line lung cancer patients.
- Brain metastasis patients showed a 47% intracranial response rate, with 41% achieving a complete response.
- Early circulating tumor DNA clearance occurred in 80% of evaluable patients, correlating with improved survival metrics.
- ArriVent BioPharma, Inc. is advancing the therapy into a global Phase 3 clinical study called ALPACCA.

## Questions and answers

### What were the key Phase 1b trial results for firmonertinib?

In front-line lung cancer patients, firmonertinib achieved a 68% response rate and 16.0 months progression-free survival at a 240 mg dose, along with strong tumor DNA clearance.

### Did ArriVent BioPharma's drug show effectiveness against brain metastases?

Yes, firmonertinib demonstrated a 47% confirmed intracranial response rate in patients with brain metastases, including complete responses in 41% of cases.

### What is the next step for ArriVent BioPharma's firmonertinib trial?

ArriVent BioPharma, Inc. is progressing the treatment into a global Phase 3 clinical study known as ALPACCA.